Health
AI Drug Discovery Pioneer, Nanyang Biologics Pte. Ltd., Enters into Business Combination Agreement with RF Acquisition Corp II in US$1.5B Transaction to Pursue Public Listing
* Nanyang Biologics Pte. Ltd., together with its subsidiaries (collectively, the "Company", "we" or "NYB"), offers a comprehensive drug discovery platform that integrates the wisdom of traditional medicine with state-of-the-art technologies. * Patented Flagship NB-A002 is a First-in-class DNA...
2025-10-02 19:50
4345
Vatech Launches 'Boundless Campaign' to Eliminate Barriers in Dental Care
First milestone: reduced device operation time update eases discomfort for elderly and disabled patients SEOUL, South Korea, Oct. 1, 2025 /PRNewswire/ -- Vatech (KOSDAQ: 043150), a global leader in dental imaging solutions, today announced the launch of its 'Boundless Campaign' a long-term initia...
2025-10-01 21:00
1289
MD Logistics Makes Largest Indiana Business Location Fully cGMP-compliant
- Total Area of 37,000m2, Enhanced Pharmaceutical Logistics Capacity - TOKYO, Oct. 1, 2025 /PRNewswire/ -- MD Logistics LLC (hereinafter "MD Logistics"), a group company of NIPPON EXPRESS HOLDINGS, INC., completed renovation of the South Area of its largest logistics base inPlainfield, in the U....
2025-10-01 15:00
1284
TAHO Pharma Announces Submission of New Drug Application (NDA) to the U.S. FDA for TAH3311 - The World's First Apixaban Oral Dissolving Film - Represents a Transformational Advancement in Anticoagulant Therapy
TAIPEI, Oct. 1, 2025 /PRNewswire/ -- TAHO Pharmaceuticals Ltd. ("TAHO Pharma") today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TAH3311, the world's first Apixaban Oral Dissolving Film (ODF). This submission marks a significant re...
2025-10-01 14:16
1366
Neurophet Publishes Clinical Validation Results of 'Neurophet AQUA' in Annals Academy of Medicine Singapore
- Clinical study conducted at the Dementia Research Centre, Nanyang Technological University,Singapore, involving Southeast Asian participants - Expert level accuracy, while significantly reducing analysis time for white matter hyperintensity and gray matter volume SEOUL, South Korea, Sept. 30, ...
2025-09-30 21:00
1095
Full-Life Technologies Announces US$77 Million Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Manufacturing Capabilities
* Series C led by Junson Capital along with new investor syndicate and existing shareholders * Funding will further advance Full-Life's global radiopharmaceutical pipeline and manufacturing capabilities inBelgium * Additional debt financing provides an alternative financing solution for Ful...
2025-09-30 08:00
1415
Lumonus Announces Transformative Multi-Year Licensing Agreement with Smarter Radiation Oncology® to bring evidenced-based directives to U.S. cancer centers
NEW YORK and SYDNEY, Sept. 29, 2025 /PRNewswire/ -- Lumonus
2025-09-30 00:00
1214
United Imaging Announces the uDR® Aurora CX
"Designed for Freedom," the newly FDA-cleared system will be showcased at RSNA. HOUSTON, Sept. 29, 2025 /PRNewswire/ -- United Imaging has announced its new digital radiography system,uDR Aurora CX, which is intended to introduce computer vision, automation, and AI diagnostics into one of the mo...
2025-09-30 00:00
1092
Smartee Chief Scientist Prof. Gang Shen Recognized Among World's Top 2% Scientists for Orthodontic Contributions
SHANGHAI, Sept. 29, 2025 /PRNewswire/ -- Smartee Denti-Technology today announced that Professor Gang Shen, its Chief Scientist and Executive President of TaiKang ByBo Dental, has once again been named to theWorld's Top 2% Scientistslist, compiled by Stanford University in partnership with Elsevi...
2025-09-29 17:56
1047
Hanmi's Oral Delivery Platform Compound Licensed to Gilead
Hanmi and HHP will grant Gilead an exclusive license to Encequidar and provide access to drug supply. SEOUL, South Korea, Sept. 29, 2025 /PRNewswire/ -- Hanmi Pharm announced on September 29 that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("Gile...
2025-09-29 17:45
956
Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical R&D ecosystem. SHANGHAI, Sept. 29, 2025 /PRNewswire/ -- Viva Biotech announced today that it has been honored...
2025-09-29 17:00
847
International Health Experts: China's Experience Benefits Global Health Governance
BEIJING, Sept. 28, 2025 /PRNewswire/ -- A news report from Xinhua Finance, "Over the past few years, we have seenChina gradually increase its universal health coverage, boost investment, and place great emphasis on preventive medicine. While advancing its 'Healthy China 2030' initiative,China has...
2025-09-28 20:50
1338
The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development
SINGAPORE, Sept. 26, 2025 /PRNewswire/ -- The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully concluded fromSeptember 24-26, 2025. The conference brought together leading biopharmaceutical companies and rese...
2025-09-27 10:45
3566
Datasea Reports Record Fiscal Year 2025 Revenue of $71.62 Million, Up 199% Year-over-Year
DTSS Achieves Fourth Quarter Net Income Breakeven Driven by Cutting-Edge Acoustics and AI Multimodal Digitalization; Ongoing Commercialization Updates in the Coming Weeks BEIJING, Sept. 26, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based high-tech ente...
2025-09-26 21:30
4582
Concord Medical Reports Financial Results for the First Half of 2025
BEIJING, Sept. 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced its unaudited consolidated financial results for t...
2025-09-26 19:30
3169
Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
BEIJING, SHANGHAI and BOSTON, Sept. 25, 2025 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK)today announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the Company by 11.06 million shares, repr...
2025-09-26 08:47
1558
Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001
BOSTON, Sept. 25, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation, today announced two landmark achievements for its lead program, BBT001. Last week, Ba...
2025-09-25 22:04
1679
The FDA Granted Orphan Drug Designation to Biostar Pharma's Utidelone for the Treatment of Pancreatic Cancer
SAN FRANCISCO, Sept. 25, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the US wholly-owned subsidiary of Beijing Biostar Biopharmaceutical Co., Ltd. ("Biostar," stock code: 2563.HK) which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of ...
2025-09-25 21:37
1797
Flat Medical Establishes Clinical Advisory Board for Pain Interventions, Names Dr. Krishnan Chakravarthy as Chairman
AUSTIN, Texas, Sept. 25, 2025 /PRNewswire/ -- Flat Medical, a leading innovator in medical device solutions, today announced the formation of itsClinical Advisory Board for Chronic Pain Interventions and the appointment of Dr. Krishnan Chakravarthy, MD, PhD, as its inaugural Chairman. This strate...
2025-09-25 21:00
1543
WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability
* TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. * The platform has achieved an average mAb titer exceeding 8.0 g/L with over 99% of clonal cell lines maintaining sta...
2025-09-25 19:42
1537
Week's Top Stories
Most Reposted
Senetas and Nokia Announce Strategic Alliance to Secure Mission-Critical Networks for Defence and Government
[Picked up by 312 media titles]
2025-11-27 07:25World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery
[Picked up by 296 media titles]
2025-12-03 09:00
SpeQtre, the entanglement-based quantum comms demonstrator satellite, is now on orbit
[Picked up by 295 media titles]
2025-11-29 09:00
Blackpanda and ST Engineering Partner to Strengthen Cyber Incident Response Across Asia
[Picked up by 285 media titles]
2025-12-03 14:27
MetaOptics Announces Strategic Share Placement to Accelerate Growth and Meet Rising Global Demand
[Picked up by 284 media titles]
2025-12-01 08:30Most Read
MINISO Unveils Australia's First and Largest MINISO LAND Flagship at Sydney Chatswood
2025-11-27 18:56
2734
